First-generation antipsychotic long-acting injections*

Mark Taylor and Polash Shajahan

in Antipsychotic long-acting injections

Published on behalf of Oxford University Press

Published in print October 2010 | ISBN: 9780199586042
Published online February 2013 | e-ISBN: 9780191754708 | DOI:
First-generation antipsychotic long-acting injections*

Show Summary Details


In this chapter we provide an up to date review of the evidence base surrounding the use of first-generation antipsychotic long-acting injections (FGA-LAIs) in schizophrenia and bipolar disorder. We start by considering the historical background to long-acting antipsychotic medications and the current patterns of use within the United Kingdom, before systematically reviewing the randomized controlled studies (RCTs) and observational studies concerning FGA-LAIs (both placebo and active comparator) in the treatment of schizophrenia and bipolar disorder. It is important to consider all study designs because different studies assess different outcomes i.e. RCTs assess efficacy—does a drug lead to benefit in ideal circumstances? Whereas observational studies assess effectiveness—does a drug have benefit in the real world where dose, patient characteristics, and follow-up may be far more variable than in an RCT? A summary section attempts to synthesize these results. We then consider the implications for future research and clinical practice.

Chapter.  8107 words.  Illustrated.

Subjects: Psychiatry

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.